Table 3.
Baseline median and trend in monthly PDC for OH and AH medicines, and changes in level and trend by stage of the ‘FP’ programme, Brazil, 2008–2012
| Baseline | AFP-II (Apr 2009) | SNP (Feb 2011) | ||||||||
| Level (PDC) | Trend | PDC (Mar 2009) | Level AFP-II (change at the intervention) | Trend AFP-II | % Relative change (AFP-II) (Apr 2010) |
PDC (Jan 2011) | Level SNP (change at the intervention) |
Trend SNP | % Relative change (SNP) (Feb 2012) |
|
| OH | 59.67 | 0.30 | 64.22 | −8.1 (−12.85;−3.36) | 0.28 (−0.12;0.67) | −9.0 | 67.21 | 4.88 (0.37;9.39) | −0.43 (−0.79;−0.07) | 2.5 |
| Glibenclamide 5 mg | 61.40 | 0.56 | 69.75 | −15.23 (−19.65;−10.81) | −0.07 (−0.43;0.3) | −20.4 | 65.73 | 6.23 (2.03;10.42) | −0.35 (−0.68;−0.01) | 5.3 |
| Metformin 850 mg | 59.02 | 0.38 | 64.74 | −10.41 (−15.3;−5.52) | 0.21 (−0.2;0.62) | −12.8 | 66.08 | 3.84 (−0.81;8.49) | −0.37 (−0.74;−0.01) | 1.7 |
| *Metformin 500 mg | 56.24 | 0.05 | 57.04 | −1.75 (−7.23;3.73) | 2.87 (0.07;5.67) | 6.7 | 64.41 | 8.56 (2.9;14.22) | −0.15 (−0.77;0.46) | 11.2 |
| Metformin slow release | 61.09 | 0.15 | 63.29 | 0.61 (−10.35;11.57) | 0.16 (−0.75;1.06) | 2.6 | 69.67 | 11.09 (0.61;21.56) | −0.43 (−1.25;0.4) | 11.0 |
| Oral AH | 63.98 | 0.45 | 70.74 | −10.63 (−14.7;−6.55) | 0.22 (−0.12;0.55) | −11.9 | 73.48 | 4.87 (1;8.73) | −0.57 (−0.88;−0.27) | 1.0 |
| *Atenolol 25 mg | 64.88 | 0.02 | 65.15 | −0.70 (−5.53;4.13) | 3.4 (1.03;5.78) | 9.1 | 74.27 | 10.63 (6.6;14.67) | −0.14 (−0.49;0.21) | 12.6 |
| Propranolol 40 mg | 61.34 | 1.07 | 77.40 | −26.21 (−32.49;−19.93) | −0.73 (−1.25;−0.21) | −34.3 | 63.00 | 11.63 (5.66;17.6) | −0.23 (−0.71;0.24) | 14.8 |
| Hydrochlorothiazide 25 mg | 56.88 | 0.82 | 69.22 | −18.17 (−22.91;−13.43) | −0.12 (−0.51;0.28) | −23.8 | 67.25 | 10.1 (5.6;14.6) | −0.53 (−0.89;−0.17) | 8.4 |
| Captopril 25 mg | 63.81 | 0.99 | 78.66 | −23.07 (−28.85;−17.29) | −0.52 (−1;−0.04) | −29.2 | 69.11 | 5.86 (0.37;11.35) | −0.38 (−0.82;0.06) | 4.2 |
| *Enalapril 5 mg | 70.16 | 0.02 | 70.39 | −2.91 (−7.74;1.93) | 2.56 (0.18;4.95) | 3.0 | 74.93 | 7.79 (3.75;11.83) | −0.02 (−0.37;0.34) | 10.0 |
Significant values p<0.05 are highlighted in bold.
*It used the Log of the AFP-II trend.
AFP-II, Aqui tem Farmácia Popular II; AH, antihypertensive; FP, Farmácia Popular; NA, no applicable; OH, oral hypoglycaemic; PDC, proportion of days covered; SNP, Saúde Não Tem Preço.